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Disrupted Maturation of the 
Microbiota and Metabolome 
among extremely preterm Infants 
with postnatal Growth Failure
Noelle e. Younge1, Christopher B. Newgard2,3,4, C. Michael Cotten1, Ronald N. Goldberg1, 
Michael J. Muehlbauer2, James R. Bain  2,4, Robert D. stevens2,4, thomas M. o’Connell2,5, 
John F. Rawls6, patrick C. seed7 & patricia L. Ashley1
Growth failure during infancy is a major global problem that has adverse effects on long-term health 
and neurodevelopment. Preterm infants are disproportionately affected by growth failure and its 
effects. Herein we found that extremely preterm infants with postnatal growth failure have disrupted 
maturation of the intestinal microbiota, characterized by persistently low diversity, dominance of 
pathogenic bacteria within the Enterobacteriaceae family, and a paucity of strictly anaerobic taxa 
including Veillonella relative to infants with appropriate postnatal growth. Metabolomic profiling 
of infants with growth failure demonstrated elevated serum acylcarnitines, fatty acids, and other 
byproducts of lipolysis and fatty acid oxidation. Machine learning algorithms for normal maturation of 
the microbiota and metabolome among infants with appropriate growth revealed a pattern of delayed 
maturation of the microbiota and metabolome among infants with growth failure. Collectively, we 
identified novel microbial and metabolic features of growth failure in preterm infants and potentially 
modifiable targets for intervention.
Postnatal growth failure is a pervasive problem among preterm infants that occurs during a critical developmen-
tal period. Previous studies have shown that the extrauterine growth rates of extremely preterm (EPT) infants 
(i.e., birth gestational age ≤27 weeks) almost universally fall below reference in utero growth rates, and approx-
imately half of infants remain below the 10th percentile in weight at the time of neonatal intensive care unit 
(NICU) discharge1,2. Compared with full term infants, preterm infants have lower weight, length, and lean body 
mass at full term-equivalent age, but higher percent body fat3. Poor growth in the NICU is a risk factor for poor 
neurodevelopmental outcomes, including cognitive and motor impairment, and the metabolic adaptations asso-
ciated with early life growth failure may predispose preterm infants to obesity and other adverse cardiometabolic 
outcomes in later life4–6.
The etiology of postnatal growth failure in EPT infants is complex and multifactorial. Major contributing fac-
tors include inadequate nutrition, immaturity of the digestive and metabolic systems, high metabolic demands, 
and critical illness7,8. Previous research has focused on preventing and correcting nutritional deficits in preterm 
infants, leading to widespread adoption of proactive nutritional practices in the NICU, including early provision 
of parenteral and fortified enteral nutrition9. However, many infants continue to experience growth failure despite 
modern nutritional management2.
The intestinal microbiota has an integral role in nutrient utilization and the regulation of host metabolism. 
Previous human and animal studies have identified microbial and metabolic signatures associated with obesity 
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and insulin resistance10–12. Recent studies have demonstrated that childhood malnutrition is associated with per-
sistent immaturity of the gut microbiota13–15. Transplantation of the microbiota of malnourished children to 
germ-free animals transmits a phenotype of impaired growth and metabolism, indicating a causal relationship 
between the microbiota and malnutrition15. The extent to which the intestinal microbiota influences metabolism 
and growth in preterm infants is unknown. The early life experiences of EPT infants are vastly different from full 
term infants in terms of medical treatments, diet, and environmental exposures. Further, microbial colonization 
of the EPT infant occurs at a much earlier stage of intestinal and immune development. Studies have shown 
stark differences in the microbiota composition of preterm infants compared to full term infants16,17. There are 
a number of potential mechanisms by which the altered microbiota and the bioactive metabolites produced by 
microbial metabolism may affect growth and metabolism in preterm infants, including direct effects on nutrient 
acquisition and utilization as well as indirect effects on intestinal development, inflammation, and hormonal 
signaling18–21.
To investigate the relationships between the intestinal microbiota, host metabolism, and growth, we conducted 
a longitudinal, prospective cohort study of EPT infants throughout their NICU hospitalization. We hypothesized 
that the diagnosis of severe postnatal growth failure would be preceded by perturbations in the development of 
the microbiota and host metabolome.
Results
We enrolled 60 EPT infants with a median birth gestational age of 26 (IQR: 24–27) weeks and birth weight of 
800 (IQR: 658–895) grams. When the infants reached 40 weeks’ postmenstrual age (PMA; defined as birth ges-
tational age plus chronologic age) or hospital disposition, 36 (60%) infants had severe postnatal growth failure 
(defined as weight less than the third percentile on sex-specific Fenton growth charts) and 22 (37%) infants had 
appropriate growth22. Two (3%) infants died prior to 40 weeks’ PMA and were excluded from the analysis, result-
ing in a cohort of 58 infants for analysis. Infants with growth failure had lower birth gestational age, lower birth 
weight, and required mechanical ventilation for longer than infants with appropriate growth (Table 1). All infants 
received parenteral nutrition immediately following birth; enteral feedings were initiated and advanced in volume 
and caloric content according to a feeding protocol (Table S1). All infants received human milk as their initial 
diet. At 40 weeks’ PMA or disposition, infants with growth failure had significantly lower percentiles for weight, 
length, and head circumference than infants with appropriate growth.
Many infants in the cohort experienced medical complications of extreme prematurity, including late-onset 
sepsis (defined as culture-proven sepsis that occurred after the first 72 hours of life), necrotizing enterocolitis, 
and spontaneous intestinal perforation (Table 1). Infants with one or more of these complications were more 
likely to have growth failure than infants without these complications (88% vs. 51%, p = 0.01), and had a median 
weight percentile less than the first percentile at 40 weeks’ PMA. Given the potential confounding effects of these 
morbidities and their treatments, we conducted a secondary analysis in which we excluded infants with late-onset 
sepsis, medical or surgical necrotizing enterocolitis, and spontaneous intestinal perforation. A total of 41 infants 
remained in the secondary analysis, including 21 infants with growth failure and 20 infants with appropriate 
growth. There were no significant differences in the timing of enteral feeding initiation or in the number of days 
of antibiotics between the infants with growth failure and infants with appropriate growth (Table 1).
Growth failure is associated with altered composition and diversity of the microbiota. We used 
16S rRNA gene sequencing to compare the fecal microbiota of infants with growth failure and appropriate growth 
using samples collected in the first postnatal week (study week 0) and weekly for up to 9 weeks once the infants 
reached full enteral feedings (study weeks 1–9). Two time variables were used to measure temporal changes: study 
week was used to provide a consistent measure of the time elapsed since the infant reached full enteral feedings 
(study week 1), ensuring similar nutritional exposures between infants across the time points; PMA was used to 
provide a consistent measure of the infants’ developmental stage. In an analysis of the full cohort of 58 infants, 
we found that the microbiota of infants with growth failure had persistently low α-diversity relative to infants 
with appropriate growth, as measured by the Shannon Index (study weeks 1–9, p = 0.002; 30.7–44.7 weeks’ PMA, 
p < 0.001, Fig. 1a)23. This finding was consistent when we repeated the analysis including only the 41 infants who 
did not experience sepsis, necrotizing enterocolitis, or intestinal perforation (weeks 2–7, p < 0.001; 31.4–37.4 
weeks’ PMA, p = 0.002).
Microbial community composition varied between and within individual infants over time (Fig. S1A,B). 
Differences between infants with appropriate growth and infants with growth failure accounted for a minor 
portion of the overall variation in community composition. We examined the relative abundance of bacterial 
taxa in the microbiota among all 58 infants in the study cohort. The representation of multiple taxa differed 
between infants with growth failure and appropriate growth. The microbiota of infants with growth failure had 
greater relative abundance of Staphylococcaceae in the early study weeks, followed by a persistent dominance of 
Enterobacteriaceae over the later weeks (Fig. 1b,c; Table S2). At the genus level, the microbiota of infants with 
growth failure had greater relative abundance of multiple Enterobacteriaceae members, including Citrobacter, 
Enterobacter, Serratia, Klebsiella, and others (Fig. 1d; Table S3). The microbiota of infants with appropriate growth 
had greater abundance of Veillonellaceae over study weeks 2–9, as well as Streptococcaceae, Peptostreptococcaceae, 
Micrococcaceae, Lachnospiraceae, and Bacillaceae over various intervals (Fig. 1b,c; Table S2). The taxonomic dif-
ferences between groups were similar when only infants without sepsis, necrotizing enterocolitis, and intestinal 
perforation were included in the analysis (Tables S2, S3), as well as when PMA was used as the time variable in 
place of study week (Table S4). Many genera had a greater relative abundance in the appropriate growth group 
at an early PMA, followed by a greater abundance in the growth failure group at later time points, potentially 
indicating delayed microbiota maturation in growth failure (e.g., Enterococcaceae unclassified, Escherichia, 
Pseudocitrobacter, Erwinia, Cedaceae, Aquimonas, Finegoldia).
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Recognizing that growth is dynamic over the course of the NICU stay, we also investigated microbiota fea-
tures associated with catch-up growth, defined as a positive change in weight z-scores between consecutive 
samples, among all 58 study infants regardless of their growth outcome. Samples obtained during periods of 
catch-up growth (n = 84) had greater relative abundance of Streptococcus and many anaerobic taxa including 
Bifidobacterium, Clostridiaceae, Clostridiales, Lachnospiraceae, Peptostreptococcaceae, Veillonella; lower abun-
dance of Staphylococcus; and higher diversity (Shannon Index, p < 0.001) than infants with a negative or neutral 
change in weight z-scores (Fig. S2A,B). We examined the association between catch-up growth and the change in 
relative abundance of the top growth-discriminatory taxa. Infants who had no change or a negative change in the 
relative abundance of Veillonella or Streptococcus between consecutive weeks had significantly greater reductions 
in weight z-scores between weeks than infants who had an increase in the abundance of these taxa (p = 0.03 for 
both; Fig. S2C). Collectively, the microbiota analyses indicate that growth failure is associated with low microbial 
diversity, a paucity of Streptococcus and multiple strictly anaerobic taxa, and an enrichment of Staphylococcus and 
Enterobacteriaceae.
Disrupted maturation of the microbiota in growth failure. Given the apparent differences in micro-
biota composition and diversity over time, we next sought to compare microbiota maturation between infants 
with growth failure and appropriate growth across the complete 58 infant cohort. Random forest regression was 
used to model maturation of the microbiota among infants with appropriate growth following the approach of 
Subramanian, et al.13. Rarefied operational taxonomic unit (OTU) counts were regressed against the infant’s PMA 
at the time of sampling. The top age-discriminatory OTUs were ranked in order of their contribution to model 
accuracy and cross-validation was used for feature selection. A total of 21 OTUs were retained in a sparse model, 
as increasing the number of variables above 21 had little impact on model error (Fig. 2a). The resulting model 
fit was significant when compared to a null distribution based on 1000 permutations of PMA (p = 0.001). The 
microbiota age predicted by the model was plotted against PMA and a smoothing spline was fit (Fig. 2b). The 
All Infants
Infants without Sepsis, Necrotizing 









Gestational age (wks), med (IQR) 27 (26, 27) 25 (24, 26)* 27 (26, 27) 26 (25, 27)*








    Asian 3 (14) 3 (8) 3 (15) 1 (5)
    Black or African American 13 (59) 16 (44) 11 (55) 10 (48)
    White 5 (23) 17 (47) 5 (25) 10 (48)
    Unknown or not reported 1 (5) 0 (0) 1 (5) 0 (0)
Female sex, n (%) 12 (55) 18 (50) 10 (50) 10 (48)
Multiple gestation, n (%) 8 (36) 9 (25) 8 (40) 5 (24)
Antenatal steroids, n (%) 22 (100) 34 (94) 20 (100) 20 (95)
Antenatal antibiotics, n (%) 16 (73) 24 (67) 15 (75) 12 (57)
C-section delivery, n (%) 17 (77) 27 (75) 15 (75) 15 (71)
Growth outcomes
Weight percentile, med (IQR) 10 (6, 14) <1 (<1, 1)* 10 (7, 16) <1 (<1, 1)*
Length percentile, med (IQR) 7 (2, 11) <1 (<1, <1)* 7 (3, 11) <1 (<1, <1)*
Head circumference, med (IQR) 25 (9, 41) 2 (<1, 6)* 26 (15, 44) 2 (<1, 6)*
Morbidities and Therapies
Late-onset sepsis, n (%) 1 (5) 6 (17) 0 (0) 0 (0)
Spontaneous intestinal perforation, n (%) 0 (0) 6 (17) 0 (0) 0 (0)
Medical necrotizing enterocolitis, n (%) 1 (5) 3 (8) 0 (0) 0 (0)
Surgical necrotizing enterocolitis, n (%) 0 (0) 4 (11) 0 (0) 0 (0)
Severe intraventricular hemorrhage, n (%) 2 (9) 3 (8) 2 (10) 1 (5)
Severe retinopathy of prematurity, n (%) 2 (9) 13 (36)* 2 (10) 7 (33)
Ligation of patent ductus arteriosus, n (%) 2 (9) 9 (25) 2 (10) 4 (19)
First day enteral feeds, med (IQR) 4 (3, 5) 5 (4, 9) 4 (3, 5) 5 (3, 10)
Day of first full feeds sample collection, med (IQR) 28 (20, 38) 42 (30, 55)* 26 (19, 38) 35 (25, 42)
Initial days antibiotics, med (IQR) 2 (2, 7) 2 (2, 6) 2 (2, 7) 2 (2, 6)
Total days antibiotics, med (IQR) 15 (8, 20) 20 (12, 37) 12 (8, 19) 14 (11, 25)
Initial days mechanical ventilation, med (IQR) 3 (1, 6) 9 (2, 19)* 3 (1, 5) 11 (2, 18)*
Total days mechanical ventilation, med (IQR) 4 (2, 12) 19 (8, 27)* 3 (2, 11) 16 (4, 22)*
Table 1. Clinical Characteristics. Continuous variables compared by Wilcoxon rank-sum test and categorical 
variables by Fisher’s exact test. *p < 0.05.
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21-feature model was then applied to a separate cohort of 15 preterm infants with appropriate growth (median 
birth gestational age 28 [range: 25–31] weeks) and a similar rise in microbiota maturity age was seen with PMA 
(Fig. 2c). Last, the model was applied to the samples from infants with growth failure (Fig. 2d). The predicted 
microbiota maturity ages of most of the growth failure samples fell below the curve derived from the infants with 
appropriate growth, suggesting that the infants with growth failure had delayed or disrupted maturation of the 
microbiota. The taxa in the model included Streptococcus, Peptostreptococcaceae, Veillonella, and others (Fig. 2e). 
Relative microbiota maturity and microbiota-for-age Z (MAZ) scores were significantly lower among infants 
with growth failure than infants with appropriate growth in the primary and validation cohorts (p < 0.001 for 
both; Fig. 2f,g). Microbiota maturity age remained significantly lower among the infants with growth failure after 
excluding infants with sepsis, necrotizing enterocolitis, and intestinal perforation (Fig. 2f). Given the potential 
influence of birth gestational age on microbiota maturation17, we compared relative microbiota maturity between 
infants with growth failure and infants with appropriate growth stratified by birth gestational age (i.e., completed 
weeks of gestation at birth). Relative microbiota maturity age was significantly lower in growth failure regardless 
of birth gestational age (Fig. 2h).
postnatal growth failure is associated with altered metabolism. We next compared serum metab-
olomic profiles of infants with growth failure and appropriate growth, including all 58 infants in the cohort. 
Flow-injection, targeted, tandem mass spectrometry (FI-MS/MS) was used to measure a panel of amino acids 
and acylcarnitines, followed by further characterization of acylcarnitines by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). Gas chromatography-mass spectrometry (GC-MS) was used for non-targeted metab-
olomic analysis. No significant differences were observed between the two groups in the first postnatal week (study 
week 0) by univariate analyses of individual metabolites or by multivariate partial least squares-discriminant anal-
ysis of the combined targeted amino acids, acylcarnitines, and non-targeted metabolites. Metabolomic profiles 
clustered by postnatal day at sampling, primarily driven by shifts in acylcarnitine concentrations (Fig. S3A,B), 
likely reflecting maturation and nutritional changes in the first postnatal week (Table S1).
Next, we compared metabolomic profiles between the two growth groups over time in the full 58 infant 
cohort, including samples that were collected while the infants were receiving full enteral nutrition. We per-
formed principal components analysis on the combined amino acid, acylcarnitine, and metabolites measured 
by non-targeted GC/MS to visualize the relationships between the infants with growth failure and infants with 
appropriate growth. We noted variation between the metabolic profiles over time and between the two groups 
(Fig. S3C). We then compared individual metabolites between infants with growth failure and appropriate growth 
over time. There were modest differences in amino acid concentrations over various intervals, including higher 
concentrations of glutamine/glutamic acid and proline in infants with growth failure and higher concentrations 
Figure 1. Microbiota diversity and composition. (a) Shannon diversity was higher over weeks 1–9 in 
appropriate growth (blue) vs. growth failure (green) (compared by SS-ANOVA with study week as continuous 
variable, p = 0.002). (b) Bacterial families with significant differences in relative abundance between groups by 
SS-ANOVA. The shaded areas represent the time intervals over which the abundance was higher in appropriate 
growth (blue) or growth failure (red). (c) Relative abundance of the top 10 bacterial families over time. (d) 
Bacterial genera with higher relative abundance in appropriate growth (blue) or growth failure (red) by SS-
ANOVA. AG, appropriate growth. GF, growth failure.
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of methionine and histidine in infants with appropriate growth, but these differences were not significant in the 
analysis of infants without sepsis, necrotizing enterocolitis, or intestinal perforation (Table S5).
We next examined acylcarnitine concentrations in all study infants. The concentration of most acylcarnitines 
decreased over time, but there were persistent elevations in a number of short- and medium-chain acylcarnitines 
in the growth failure group relative to the appropriate growth group (Fig. S4A,B). Concentrations of certain 
long-chain acylcarnitines (e.g., C18:1, C18:2, C20:4) were higher in the appropriate growth group (Fig. S4B). 
These findings were similar when the analysis was restricted to infants without sepsis, necrotizing enterocolitis, or 
intestinal perforation, with higher concentrations of multiple medium-chain acylcarnitines in the growth failure 
group, and higher long-chain acylcarnitines in the infants with appropriate growth (Table S6). Similar temporal 
changes and relationships between groups were observed in the larger set of acylcarnitines measured by LC-MS/
MS (Fig. S4C).
In the non-targeted GC-MS metabolomic analysis of the full 58 infant cohort, infants with growth failure 
had higher levels of multiple fatty acids and their products of oxidation, including palmitoleic acid, lauric acid, 
the fatty acid-derived ketone body β-hydroxybutyric acid, and the diacidic fatty acid, azelaic acid, which can be 
formed during ω-oxidation (Fig. S5A). The findings were similar in the cohort of infants without sepsis, necrotiz-
ing enterocolitis, or intestinal perforation (Fig. S5B). These changes were accompanied by increases in glycerol, a 
byproduct of lipolysis in adipose tissue. Overall, these results suggest that infants with growth failure have altered 
metabolic development relative to infants with appropriate growth, particularly related to lipolysis and fatty acid 
oxidation.
Disrupted maturation of the metabolome in growth failure. Given the apparent differences in 
metabolic development between infants with growth failure and infants with appropriate growth, we used the 
same random forest regression approach as described in the microbiota analysis, but with metabolites in place of 
microbial taxa, to model maturation of the metabolome in infants with appropriate growth. The resulting model 
explained 80% of the variation in relation to postmenstrual age (p = 0.004). We retained the top 8 features in a 
reduced model based on cross-validated prediction performance of the model with sequentially fewer variables 
(Fig. 3a). The top features in the appropriate growth model included octanoyl carnitine, 3-methylglutaryl carni-
tine, hexenoyl (C6:1) carnitine, 2-methylbutyrl carnitine, and octenoyl (C8:1) carnitine, which decreased over 
time, and octadecenoyl (C18:1) carnitine, hexadecenoyl (C16:1) carnitine, and dodecenoyl (C12:1) carnitine, 
which increased over time (Fig. 3b). The reduced 8-feature model was applied to the appropriate growth infants 
(R2 = 80%, p = 0.005) and a smoothing spline was fit (Fig. 3c). The model was then applied to the infants with 
growth failure, and the relative metabolic maturity was compared to the spline derived from the infants with 
appropriate growth (Fig. 3d). Infants with growth failure had significantly lower relative metabolic maturity and 
metabolome-for-age Z scores (p < 0.001), indicating that growth failure is associated with delayed metabolic 
maturation. Metabolic maturation was also significantly delayed in growth failure in the cohort of infants without 
sepsis, necrotizing enterocolitis, or intestinal perforation (Fig. 3d–f). We also examined the relationship between 
metabolic maturation and birth gestational age. Relative metabolic maturity did not differ significantly between 
birth gestational age strata (i.e., completed weeks of gestation at birth). Median relative metabolic maturity was 
lower among infants with growth failure than infants with appropriate growth when compared within birth ges-
tational age groups (Fig. 3g).
Relationships between the microbiota and metabolome. To elucidate relationships between micro-
bial communities and metabolic functions, we used partitioning around medoid (PAM) clustering to group all 
microbiota samples into 6 clusters (Fig. 4a,b). The distribution of clusters differed between growth groups and 
with time (Fig. 4c). At later time points, samples were more likely to be included in Clusters 1, 2, and 6, and 
less likely to fall into Clusters 3 and 5 (p < 0.01 for all). Growth failure was associated with Cluster 3 (p = 0.02). 
Clusters 3 and 5 were associated with greater reductions in weight z-scores between weeks than Clusters 1, 2, 
4, and 6 (Fig. 4d). The microbiota samples were paired with the corresponding metabolomic samples that were 
collected from the same individual and time point, and metabolite set enrichment analysis was used to identify 
metabolite sets that were enriched in each cluster (Fig. 4e). The metabolomic profiles of samples linked to the 
samples in the growth failure-associated Cluster 3 were enriched in several lipid metabolism pathways includ-
ing fatty acid β-oxidation, glycerolipid metabolism, phospholipid biosynthesis, and branched-chain fatty acid 
oxidation.
We explored the relationship between Cluster 3 with its nearest neighbors Clusters 1 and 6 (Fig. 4b). All 
three clusters were enriched in a common Serratia OTU, but Cluster 3 was associated with poor growth relative 
to Clusters 1 and 6, suggesting that the poor growth may be related to a paucity of taxa enriched in Clusters 1 
and 6 rather than the Serratia dominance. Taxa co-enriched in Clusters 1 and 6 relative to Cluster 3 included 
Veillonella (Cluster 1) and Peptostreptococcaceae (Clusters 1 and 6). We explored correlations between Veillonella 
and Peptostreptococcaceae OTUs and individual host metabolites. These taxa were positively correlated with cer-
tain amino acids and amino acid metabolites (e.g., Veillonella with histidine; Peptostreptococcaceae with citrulline 
and indoleacetic acid) and negatively correlated with indolelactic acid and multiple acylcarnitines (Fig. S6).
Discussion
We found that EPT infants with postnatal growth failure had disrupted maturation of the microbiota charac-
terized by low diversity, persistent dominance of Enterobacteriaceae, and a paucity of strictly anaerobic taxa 
including Veillonella compared to infants with appropriate growth. Further, the infants with growth failure 
demonstrated a metabolic signature of increased lipolysis and fatty acid oxidation, characterized by elevations in 
multiple fatty acids, acylcarnitines, glycerol, and β-hydroxybutyric acid. Under normal physiological conditions, 
fatty acid mobilization and oxidation are enhanced in the fasted compared to the fed state. Malnourished children 
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in Uganda present with a similar profile of elevated fatty acids, acylcarnitines and ketone metabolites, all of which 
are lowered by a two-week period of nutritional rescue24. In contrast, the infants with growth failure in our study 
had a persistent physiologic state resembling fasting despite similar caloric intake as the infants with appropriate 
growth. This may suggest that infants with growth failure have deficiencies in anabolic metabolism of glucose 
and other non-lipid fuels, leading to a greater reliance on fatty acids to meet metabolic demands. Interestingly, 
transplantation of microbial communities from malnourished children in Malawi into germ-free mice results 
Figure 2. Maturation of the microbiota. A 21-feature random forest regression model was constructed with 
the appropriate growth samples (R2 = 58%, p = 0.001). The number of features was selected by cross-validation 
(a). The predicted microbiota maturity age increased with postmenstrual age (b). The model was applied to a 
separate cohort of infants with appropriate growth (c) and to infants with growth failure (d). The spline derived 
from the appropriate growth infants in the primary cohort is shown in each panel (b–d). The 21 features in 
the model and their abundance (rarefied counts) over time (i.e., postmenstrual age) are shown (e). Relative 
microbiota maturity and microbiota-for-age Z scores were similar in the two appropriate growth cohorts, 
but significantly lower in growth failure (f,g). Microbiota maturity was also significantly lower when the 
analysis was restricted to infants without sepsis, necrotizing enterocolitis, or intestinal perforation (f). Relative 
microbiota maturity age was lower in infants with growth failure than infants with appropriate growth when 
infants were stratified by gestational age at birth (h). **p < 0.05 by pairwise Wilcoxon rank sum test with 
Benjamini-Hochberg adjustment. AG, appropriate growth. GF, growth failure. LOS, late-onset sepsis. NEC, 
necrotizing enterocolitis. SIP, spontaneous intestinal perforation. Val-AG, validation cohort appropriate growth.
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in elevated levels of multiple acylcarnitine species relative to mice transplanted with the same microbiome sup-
plemented with a 5-member microbial community from healthy children14. These findings demonstrate that 
the microbiome of malnourished children can impart a metabolic phenotype indicative of enhanced fatty acid 
mobilization and oxidation, similar to that reported here. The enrichment of key pathways that are expected to 
contribute to the metabolite signature of lipid mobilization and oxidation (e.g., fatty acid oxidation pathways and 
Figure 3. Maturation of the metabolome. An 8-feature random forest regression model was constructed using 
acylcarnitine profiles of infants with appropriate growth. (a) The number of features was selected by cross-
validation. (b) Heatmap of the 8 metabolites included in the model over time, ranked in order of importance in 
the model by the percent difference in mean squared error (%IncMSE). (c) Metabolic maturity age increased 
with postmenstrual age in the appropriate growth infants. (d) The model was then applied to infants with 
growth failure. The metabolic maturity age of many of the infants with growth failure fell below the spline 
derived from infants with appropriate growth in both the primary analysis of the full 58 infant cohort and the 
secondary analysis of infants without sepsis, necrotizing enterocolitis, or intestinal perforation (shown). (e) 
Relative metabolic maturity and metabolome-for-age Z scores were significantly lower in growth failure (green) 
than in appropriate growth (blue), both when including all infants and when including only infants without 
sepsis, necrotizing enterocolitis, or intestinal perforation (shown). (g) Relative metabolic maturity was lower 
among infants with growth failure (green) than infants with appropriate growth across birth gestational age 
strata (blue); the difference between groups was statistically significant among infants born at 26 weeks and 
27 weeks of gestation. **p < 0.05, as determined by the pairwise Wilcoxon rank sum tests with Benjamini-
Hochberg adjustment. AG, appropriate growth.
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glycerolipid metabolism) in the growth failure-associated Cluster 3 suggests that the unique composition of bac-
terial communities in growth failure might contribute to a metabolic state with similarities to fasting. Our finding 
of impaired metabolic maturity in growth failure is consistent with this concept.
The etiology of growth failure in extremely preterm infants is complex and multifactorial. The persistent dif-
ferences in the microbiota and metabolome that preceded growth failure in the subgroup of infants without major 
infectious and intra-abdominal complications indicates that the observed differences are not solely attributable to 
these morbidities. However, we cannot exclude the possibility that other host or clinical confounding factors con-
tributed to the observed associations between the microbiota, metabolome, and growth. Studies in other model 
systems indicate that the early microbiota directly influences postnatal growth20,25,26. A recent study examined the 
effects of the preterm infant microbiota on intestinal maturation and gene expression in germ-free mice18,19. The 
mice were colonized with the microbiota of two preterm infants, one of whom had slower weight gain than the 
other. Recipients of the microbiota from the infant with slower growth had increased NF-kB activation, decreased 
markers of intestinal epithelial maturation, and diminished growth compared to the mice that received the micro-
biota of the infant with a higher growth rate. While the study was limited to two infants, the results suggest that 
the preterm infant microbiota may directly modulate intestinal development and postnatal growth.
Other studies provide testable models of how the altered microbiota in growth failure may modulate met-
abolic maturity. Studies in gnotobiotic models have shown that the microbiota alters both nutrient extraction 
and host genes involved in regulating energy expenditure, including fatty acid oxidation27,28. Differences in the 
functions of the microbiota and the production of bioactive metabolites by the microbiota in growth failure 
may have effects on host metabolism, as microbial metabolites such as the short-chain fatty acids have a role in 
regulating glucose homeostasis and lipid metabolism29,30. Differences in innate immune responses to the altered 
microbiota in growth failure represent another potential mediator of the microbiota-metabolome associations 
observed in our study. For example, the high burden of Enterobacteriaceae in growth failure may have led to 
increased inflammation through toll-like receptor 4 activation, which could in turn decrease insulin sensitivity 
and increase lipolysis markers, since insulin suppresses lipolysis in adipose tissue31. The finding of a low diversity 
microbiota in the infants with growth failure could also contribute to impaired growth, as low microbial diversity 
is associated with impaired barrier function and intestinal inflammatory conditions including necrotizing enter-
ocolitis in preterm infants32,33.
Two recent observational studies investigated the microbiota and preterm infant growth. Arboleya, et al. 
examined the abundance of 8 bacterial taxa in the first month of life and weight gain in infants born at 28–33 
weeks of gestation. Some of the same taxa were negatively associated with growth as in our study, including 
Staphylococcus and Enterobacteriaceae34. Grier, et al. grouped the microbiota of a cohort of preterm and full term 
infants into three phases35. Phase 2, which was enriched in Enterobacteriaceae, was associated with prematurity 
and negatively associated with weight z-scores in a multivariate regression model. The integrated analysis of the 
Figure 4. Microbiota clusters. (a) Relative abundance of the top 15 OTUs in the 6 clusters. (b) Non-metric 
multidimensional scaling (NMDS) plot of clusters. (c) The distribution of clusters by growth group and time. 
(d) Change in weight z-scores between consecutive samples. Clusters 3 and 5 were associated with significantly 
greater weight z-score reductions than samples in clusters 1, 2, 4, and 6. (e) Metabolite sets enriched in clusters. 
AG, appropriate growth; deg., degradation; FAs, fatty acids; GF, growth failure; met., metabolism.
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fecal microbiota and serum metabolome in our current study adds new insight into changes in host metabolism 
that accompany the altered microbiota in growth failure.
Additional study is needed to reproduce our findings in independent cohorts to determine if these signatures 
of microbiota and metabolomic maturation apply broadly to infants with and without growth failure. Current 
practice is limited by a lack of biomarkers to identify the infants at highest risk of growth failure, guide personal-
ized interventions, and measure the response to therapy. Simply increasing caloric supply in growth failure with-
out understanding the infant’s capacity to effectively utilize the added nutrients is often ineffective and may have 
unintended consequences, such as the accumulation of metabolites to levels that are toxic to developing organs, 
diversion of nutrients to fuel concomitant inflammatory processes, or the promotion of adiposity relative to lean 
body mass. Understanding how nutritional efficacy is altered by the infant microbiota and metabolic maturity 
may yield novel approaches to predict, prevent, and treat growth failure in preterm infants.
Methods
study design. We enrolled EPT infants in the Duke NICU, excluding infants with major congenital anom-
alies, abdominal surgery prior to enrollment, or small-for-gestational age (birth weight <10th percentile). Severe 
postnatal growth failure was defined as weight <3rd percentile on Fenton growth charts at 40 weeks’ PMA, 
or at hospital discharge for infants discharged prior to 40 weeks’ PMA. The study was approved by the Duke 
Institutional Review Board and carried out in accordance with relevant guidelines and regulations. Written 
informed consent was obtained from parents. Stool was collected from diapers. Serum samples were scavenged 
from blood that was collected for routine laboratory testing. Samples were stored at −80 °C until analysis.
Microbiome analysis. Genomic DNA was extracted from fecal samples using bead-beating and extrac-
tion kits (Zymo Research). PCR was performed using primers targeting the V4 region (515F/806R) of the 16S 
rRNA gene36. PCR amplicons were pooled and sequenced on the Illumina MiSeq platform. Sequences were fil-
tered, trimmed, and paired ends were overlapped using QIIME scripts37, resulting in a median of 42,546 (IQR: 
30464, 65609) high quality reads per sample. Reads with >97% shared sequence identity were clustered into 
OTUs. Taxonomy assignments were made by aligning representative sequences to the SILVA database38. OTUs 
in Enterobacteriaceae family that did not have a lower taxonomic assignment were further classified using the 
RDP classifier39. Sparse OTUs that did not have counts of more than 10 in at least 10% of samples and samples 
with <50 filtered reads were removed. A total of 385 samples were analyzed, including a median of 6 (IQR: 4, 8) 
samples per subject in the cohort of infants without sepsis, necrotizing enterocolitis, or intestinal perforation.
Metabolomic analysis. Targeted FI-MS/MS was used to quantify a panel of 45 acylcarnitines and 15 amino 
acids in the infant serum using stable isotope dilutions11,40. We removed C7:DC, which had a concentration 
below the limit of detection in >25% of the samples. Acylcarnitines were further characterized by LC-MS/MS41,42. 
Samples in which <50% of metabolites were detected and metabolites that were undetected in >25% of samples 
were removed. Zero values were replaced by half of the minimum value for each metabolite. Concentrations were 
then log-2 transformed and Pareto scaled in MetaboAnalyst 3.043. The median number of blood samples per 
subject was 8 (IQR: 6, 9).
Samples with sufficient remaining volume were analyzed by non-targeted GC-MS44,45. Quality controls were 
included in each sample batch. Annotations were assigned using an internal GC-MS spectral library. A total of 
167 features were detected, after removal of 50 features that were considered contaminants or had uncertain 
annotations. The dataset was filtered to remove metabolites that were included in the targeted data, not detected 
in all batches, or detected in <50% of samples, leaving 70 metabolites. Peak intensities were log-2 transformed 
and mean centered across five batch groups. Samples in which <50% of metabolites were detected were removed. 
The remaining missing values were imputed using K-nearest neighbor and metabolite values were Pareto scaled 
in MetaboAnalyst.
statistical analysis. Microbiome analysis. We determined the composition and diversity of the microbiota 
using functions in the phyloseq package46. We used smoothing spline analysis of variance (SS-ANOVA) models 
with 1000 permutations for between-group comparisons over time47–49. Sequencing counts were normalized by 
cumulative sums scaling47. The relative abundance of bacterial taxa at the family and genus level were compared 
between groups using the fitTimeSeries function in the metagenomeSeq package49. The relationships between 
microbiota community structure in infants with growth failure and appropriate growth were examined using 
principal coordinates analysis (PCoA) on Jensen-Shannon divergences (JSD).
Samples from the appropriate growth group were used to construct a model of microbiota maturation13. The 
trimmed OTU table from the primary cohort was used as a closed reference for OTU picking in a separate vali-
dation cohort of preterm infants with appropriate growth. Seven OTUs that were present in the primary cohort 
but not the validation cohort were removed. OTU counts were rarefied to 5000 counts. The OTU counts from the 
appropriate growth infants in the primary cohort were regressed against infant PMA at the time of sampling by 
random forest regression with 500 trees. Features were ranked in order of importance and 100-fold cross valida-
tion was used to select the number of features to retain with the rfcv function in the randomForest package50. We 
then constructed a sparse model using only the retained features that accounted for the greatest marginal differ-
ence in mean squared error. The significance of the model fit was determined by comparing the results to a null 
distribution using 1,000 random permutations of infant PMA. We plotted the predicted microbiota age by PMA 
for each sample and fit a smoothing spline. The sparse model was then applied to the infants in the validation 
cohort and the infants with growth failure. The results were compared to the spline derived from the appropriate 
growth infants. Relative microbiota maturity was defined as the predicted microbiota age of the infant minus the 
microbiota age of infants with appropriate growth at the same PMA, as determined by the smoothing spline13. 
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MAZ scores were calculated by subtracting the median microbiota age of PMA-matched appropriate growth 
infants from the predicted microbiota age, and dividing the result by the standard deviation of the microbiota 
age of PMA-matched appropriate growth infants. For this analysis, samples were grouped into four one-month 
intervals (<30, 30–33, 34–37, and >38 weeks’ PMA).
Metabolomic analyses. Metabolomic profiles of infants with growth failure and appropriate growth were com-
pared in study week 0 using t-tests for individual metabolites and partial least squares-discriminant analysis for 
metabolomic profiles. Next, temporal differences in metabolites between groups were examined using principal 
components analysis and SS-ANOVA. Metabolic maturation was modeled using the same random forest regres-
sion approach described in the microbiota analysis. The metabolomic datasets were combined retaining only 
samples with complete LC-MS/MS acylcarnitine, amino acid, and GC-MS data that were obtained from infants 
who were receiving complete enteral nutrition to minimize the confounding effects of parenteral nutrition on 
serum metabolites. Metabolite values were regressed against PMA in the appropriate growth infants. The result-
ing model explained 79% of the variation related to PMA (p = 0.001). We selected the top features to retain in a 
reduced model based on cross-validated prediction performance with sequentially fewer variables. We found that 
all of the top variables that contributed substantially to model performance were present in the LC-MS/MS acyl-
carnitine dataset, including 3-methylglutaryl, octanoyl, C18:1, 2-methylbutyryl, and C10:2 carnitine. The com-
bined metabolomics dataset of acylcarnitines, amino acids, and metabolites identified by non-targeted GC-MS 
analysis contained fewer samples than the LC-MS/MS acylcarnitine dataset due to the exclusion of samples with 
insufficient volume for GC-MS analysis. Given that all of the top predictors in the model were acylcarnitines, we 
constructed a new model using only the acylcarnitine data to maximize the number of samples included. We 
compared relative metabolic maturity and metabolome-for-age Z scores between groups, defined by the same 
criteria as in the microbiota analyses. There was no validation cohort for the metabolic maturity model.
Relationships between the microbiota and metabolome. Microbiota samples were clustered using PAM including 
the most significant PCoA eigenvectors from a JSD matrix. The number of clusters was determined using the 
gap statistic51. Repeated measures logistic regression was used to determine whether time and study group were 
predictors of cluster, considering each cluster in a separate model as a binary outcome. Metabolomic samples 
were paired with their corresponding microbial samples and quantitative metabolite set enrichment analysis was 
performed in MetaboAnalyst 3.0. Significant metabolite sets (FDR p < 0.05) were enriched in the specified cluster 
in comparison to all other samples. We examined correlations between individual metabolites and Veillonella and 
Peptostreptococcaceae OTUs using Spearman correlation.
Statistical analyses were performed in the R environment (version 3.3.2). Data were visualized using the 
ggplot2 package52. We routinely corrected for multiple testing by the Benjamini-Hochberg method.
Data Availability
Sequencing data for this study are available under BioProject PRJNA544545.
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